

Supplemental Material

Supplemental Figure 1: Visualization of marker expression among the entire MBC and memory $CD4^+$ T cell compartments. PBMCs from *P. vivax* symptomatic (n=11) and asymptomatic (n=19) infected individuals as well as healthy immune controls (n=24) were stained with a panel of metal-labelled antibodies and analysed by CyTOF. tSNE analysis was performed on the entire MBC (A) and memory $CD4^+$ T cell compartments (C). tSNE plots display cell density and represent the pooled data for each group. Each marker used for the characterization of MBCs and memory $CD4^+$ T cells was then overlaid on tSNE plots (B and



Supplemental Figure 2: Correlations between cell populations that are differentially abundant between healthy controls and asymptomatic individuals. PBMCs from *P. vivax* symptomatic (n=11) and asymptomatic (n=19) infected individuals as well as healthy immune controls (n=24) were stained with a panel of metal-labelled antibodies and analysed by CyTOF. Unsupervised hierarchical clustering heatmap showing the frequency of differentially abundant cell populations between healthy controls and asymptomatic individuals (A). Spearman correlation networks were used to determine the relationship between cell populations that were either reduced (B) or increased (C) in healthy controls compared to individuals with an asymptomatic infection.

| Antibody | Clone | Supplier |
|------------------------------|----------|-----------|
| 141Pr-conjugated anti-CCR6 | 11A9 | Fluidigm |
| 143Nd-conjugated anti-CD45RA | HI100 | Fluidigm |
| 146Nd-conjugated anti-IgD | IA6-2 | Fluidigm |
| 147Sm-conjugted anti-CD20 | 2H7 | Fluidigm |
| 151Eu-conjugated anti-ICOS | DX29 | Fluidigm |
| 152Sm-conjugated anti-CD21 | BL13 | Fluidigm |
| 153Eu-conjugated anti-CXCR5 | RF8B2 | Fluidigm |
| 156Gd-conjugated anti-CXCR3 | G025H7 | Fluidigm |
| 158Gd-conjugated anti-CD10 | HI10a | Fluidigm |
| 165Ho-conjugated anti-CD19 | HIB19 | Fluidigm |
| 167Er-conjugated anti-CD27 | L128 | Fluidigm |
| 170Er-conjugated anti-CD3 | UCHT1 | Fluidigm |
| 172Yb-conjugated anti-IgM | MHM-88 | Fluidigm |
| 174Yb-conjugated anti-CD4 | SK3 | Fluidigm |
| 175Lu-conjugated anti-PD-1 | EH12.2H7 | Fluidigm |
| 176Yb-conjugated anti-CD127 | A019D5 | Fluidigm |
| APC-conjugated anti-IgG | M1310G05 | Biolegend |
| PE-conjugated anti-FcRL5 | 509f6 | Biolegend |
| 145Nd-conjugated anti-PE | PE001 | Fluidigm |
| 162Dy-conjugated anti-APC | APC003 | Fluidigm |

Supplemental Table 1: Surface marker antibodies for CyTOF

| Antibody | Clone | Supplier |
|-----------------------------------|------------|-----------------|
| BB515-conjugated anti-CCR6 | 11A9 | BD |
| PE-conjugated anti-CCR4 | 1G1 | BD |
| PE CF594-conjugted anti-CXCR3 | 1C6/CXCR3 | BD |
| Pacific Blue-conjugated anti-CD25 | M-A251 | Biolegend |
| AF647-conjugated anti-CXCR5 | RF8B2 | BD |
| AF532-conjugated anti-CD3e | UCHT1 | Invitrogen |
| APC-Cy7-conjugated anti-CCR7 | G043H7 | Biolegend |
| BV605-conjugated anti-CD127 | HIL-7R-M21 | BD |
| BV650-conjugated anti-CD27 | MT2T4 | BD |
| BV711-conjugated anti-PD-1 | EH12.2H7 | Biolegend |
| BV786-conjugated anti-CD4 | SK3 | BD |
| PE-Cy5-conjugated anti-CD45RA | HI100 | BD |
| FITC-conjugated anti-IgA | Polyclonal | SouthernBiotech |
| Pacific Blue-conjugated anti-CCR6 | G034E3 | Biolegend |
| APC-Fire 750-conjugated anti-IgD | IA6-2 | Biolegend |
| PE-conjugated anti-FcRL5 | 509f6 | Biolegend |
| PE-Cy7-conjugated anti-CD21 | Bu32 | Biolegend |
| APC-conjugated anti-IgG | M1310G05 | Biolegend |
| AF700-conjugated anti-CD10 | HI10a | BD |
| PerCP-Cy5.5-conjugated anti-IgE | MHE-18 | Biolegend |
| BV605-conjugated anti-IgM | MHM-88 | Biolegend |
| BV711-conjugated anti-CD19 | HIB19 | Biolegend |
| BV785-conjugated anti-CD20 | 2H7 | Biolegend |

Supplemental Table 2: Surface marker antibodies for FACS